TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04640779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Salicylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT05587257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma pen
Description: , will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niosome minoxidil
Description: The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Topical Spray
Description: The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
Study: NCT06312423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligonucleotides, Phosphorothioate
Description: Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligonucleotides, Phosphorothioate
Description: Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligonucleotides, Phosphorothioate
Description: Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
Study: NCT06461793

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients
Description: this researcher performed biodegradable material injection during radical radiotherapy in combination with hormone therapy in high - risk prostate cancer patients. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
Study: NCT05295082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided trephination-based drilling protocol
Description: the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
Study: NCT06255470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
Study: NCT04808154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP-630
Description: Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
Study: NCT06074614

Intervention type: DIAGNOSTIC_TEST
Intervention: Hypercapnic ventilatory response
Description: Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hypercapnic ventilatory response
Description: Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory related evoked potential
Description: The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory related evoked potential
Description: The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
Study: NCT04684550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stabilized hypochlorous acid
Description: Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
Study: NCT06055881

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05412719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS
Description: the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS
Description: the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
Study: NCT04509427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructional handouts
Description: Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructional handouts
Description: Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapist instruction and monitoring via teleconferencing
Description: The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapist instruction and monitoring via teleconferencing
Description: The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based instructional videos
Description: Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Posture training
Description: Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
Study: NCT04692779

Intervention type: OTHER
Intervention: Lung Ultrasound (LUS)
Description: Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
Study: NCT05745961

Intervention type: RADIATION
Intervention: TSPO PET scan (11C-PBR28)
Description: PET scan

Intervention type: RADIATION
Intervention: TSPO PET scan (11C-PBR28)
Description: PET scan
Study: NCT06583720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene at home
Description: Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene at home
Description: Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
Study: NCT04509427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Posture training
Description: Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Marching in place
Description: Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Marching in place
Description: Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
Study: NCT06451380

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthopaedic surgery
Description: orthopaedic surgery of the upper limb under anaesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthopaedic surgery
Description: orthopaedic surgery of the upper limb under anaesthesia
Study: NCT06583720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene at home
Description: Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
Study: NCT06451380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol anesthesia
Description: The initial dose of propofol and the refractory period will be determined according to a standardized protocol used in current practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol anesthesia
Description: The initial dose of propofol and the refractory period will be determined according to a standardized protocol used in current practice.
Study: NCT04600323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Tablets
Description: Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
Study: NCT06583720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene at home
Description: Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aPDT
Description: A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aPDT
Description: A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.
Study: NCT04998942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual cardiac wellness program
Description: Participants assigned to this arm will participate in the experimental intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Participants assigned to this arm will participate in a placebo intervention.
Study: NCT05338736

Intervention type: DIAGNOSTIC_TEST
Intervention: LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)
Description: Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients

Intervention type: DIAGNOSTIC_TEST
Intervention: LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)
Description: Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients

Intervention type: DIAGNOSTIC_TEST
Intervention: LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)
Description: Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients

Intervention type: DIAGNOSTIC_TEST
Intervention: LIAISON SARS-CoV2-IgM (DiaSorin)
Description: Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients

Intervention type: DIAGNOSTIC_TEST
Intervention: LIAISON SARS-CoV2-IgM (DiaSorin)
Description: Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients

Intervention type: DIAGNOSTIC_TEST
Intervention: LIAISON SARS-CoV2-IgM (DiaSorin)
Description: Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Human IFN-g ELISpot PLUS (ALP) (AUROGENE)
Description: Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)

Intervention type: DIAGNOSTIC_TEST
Intervention: Human IFN-g ELISpot PLUS (ALP) (AUROGENE)
Description: Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)

Intervention type: DIAGNOSTIC_TEST
Intervention: Human IFN-g ELISpot PLUS (ALP) (AUROGENE)
Description: Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
Study: NCT06468553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prediabetes Care Program
Description: Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
Study: NCT06010979

Intervention type: PROCEDURE
Intervention: conventional intrumentation assisted knee arthroplasty
Description: conventional intrumentation assisted knee arthroplasty

Intervention type: PROCEDURE
Intervention: computer navigation assisted knee arthroplasty
Description: computer navigation assisted knee arthroplasty

Intervention type: PROCEDURE
Intervention: robotic system assisted knee arthroplasty
Description: robotic system assisted knee arthroplasty

Intervention type: PROCEDURE
Intervention: patient-spercific assisted knee arthroplasty
Description: patient-spercific assisted knee arthroplasty
Study: NCT05295082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided Conventional drilling-based protocol
Description: the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
Study: NCT04311775

Intervention type: DEVICE
Intervention: larengeal mask insertion with video laryngoscopy
Description: it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy

Intervention type: OTHER
Intervention: laryngeal mask insertion
Description: laryngeal mask is a method of inserting atube into the upper airway
Study: NCT05257655

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI after ganglionic local opioid analgesia (GLOA)
Description: MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
Study: NCT06326385

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04600323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
Study: NCT05109728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
Study: NCT04801771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspire Upper Airway Stimulation (UAS) System
Description: The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.